TLC Announces Early Completion of Patient Enrollment in TLC590 Phase II Clinical Trial following Bunionectomy
February 12, 2020 04:00 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 12, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC Announces Dosing of First Patients in Part 2 of TLC590 Phase II Trial for Postsurgical Pain following Bunionectomy
January 08, 2020 04:00 ET
|
TLC
Part 2 will dose ~150 patients with TLC590, bupivacaine, or placeboPrimary endpoint: AUC0-72 on numerical pain rating scaleEnrollment of all patients to take ~3 months SOUTH SAN FRANCISCO, CA...
Study Demonstrates 12-Month Relief of Post-Amputation Pain Following Treatment With SPRINT PNS System
December 10, 2019 08:29 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Dec. 10, 2019 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced publication of 12-month follow up results of its...
TLC Announces First Patient Enrollment in EXCELLENCE Trial Evaluating Single and Repeat Administrations of TLC599
November 27, 2019 04:30 ET
|
TLC
Phase III clinical trial of TLC599 to recruit 500 patients with moderate to severe symptomatic knee osteoarthritis Patients can receive two injections of placebo or drugPatient enrollment expected to...
TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY® Annual Meeting and in International Journal of Nanomedicine
October 21, 2019 05:24 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC to Present as Panelist among Key Opinion Leaders at the BTIG Pain Management Forum
September 03, 2019 06:04 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 03, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152) announced today that the Company’s management team has been invited to participate in...
Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial
June 19, 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
Forty five patients were treated with escalating doses of RTX in the Phase 1b trial to date. Thirty seven patients received RTX and eight patients received saline (pooled as placebo group).Most...
TLC Announces Part 1 Analysis of TLC590 Phase II Clinical Trial for Postsurgical Pain Management following Bunionectomy
June 14, 2019 04:45 ET
|
TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 14, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor
June 10, 2019 09:00 ET
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, June 10, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced results from a pharmacokinetic study of their novel formulation of celecoxib...
Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain
June 10, 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, June 10, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that review of early results from an on-going “declawed cat pain trial” (run by its Ark...